A large proportion of hepatitis C in the developed world occurs in injection drug users. Treatment uptake in this population is low, despite the rising burden of HCV-related liver disease. Multiple barriers preclude the optimal care of hepatitis C in injection drug users, including low medication adherence and HCV re-infection.
- Vincent Soriano
- Lucía Gallego
